Corbus Pharmaceuticals (NASDAQ:CRBP) Issues Quarterly Earnings Results

Key Points

• Corbus Pharmaceuticals reported a quarterly EPS of ($1.44), missing the consensus estimate of ($1.35) by ($0.09).
• The company's stock experienced a year-to-date surge of 342%, with current shares trading at $8.80.
• Analysts have mixed views, with one sell rating, eight buy ratings, and two strong buy ratings, resulting in an average target price of $49.38.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.11, Zacks reports.

Corbus Pharmaceuticals Stock Performance

Shares of Corbus Pharmaceuticals stock traded down $0.44 on Tuesday, hitting $8.90. 137,470 shares of the company traded hands, compared to its average volume of 192,647. The business has a 50-day simple moving average of $8.36 and a 200 day simple moving average of $7.77. The stock has a market capitalization of $108.94 million, a P/E ratio of -2.11 and a beta of 3.20. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $61.89.

Analyst Ratings Changes

CRBP has been the topic of several research analyst reports. Lifesci Capital raised shares of Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Saturday, July 12th. Royal Bank Of Canada decreased their price target on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer cut their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. B. Riley upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 price objective on the stock in a report on Wednesday, July 30th. Finally, HC Wainwright cut their price objective on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $49.38.

Institutional Investors Weigh In On Corbus Pharmaceuticals

A hedge fund recently bought a new stake in Corbus Pharmaceuticals stock. AQR Capital Management LLC bought a new position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 107,983 shares of the biopharmaceutical company's stock, valued at approximately $573,000. AQR Capital Management LLC owned 0.88% of Corbus Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.